Prevalent p53 mutants co-opt chromatin pathways to drive cancer growth

TP53 (which encodes p53 protein) is the most frequently mutated gene among all human cancers. Prevalent p53 missense mutations abrogate its tumour suppressive function and lead to a ‘gain-of-function’ (GOF) that promotes cancer. Here we show that p53 GOF mutants bind to and upregulate chromatin regulatory genes, including the methyltransferases MLL1 (also known as KMT2A), MLL2 (also known as KMT2D), and acetyltransferase MOZ (also known as KAT6A or MYST3), resulting in genome-wide increases of histone methylation and acetylation. Analysis of The Cancer Genome Atlas shows specific upregulation of MLL1, MLL2, and MOZ in p53 GOF patient-derived tumours, but not in wild-type p53 or p53 null tumours. Cancer cell proliferation is markedly lowered by genetic knockdown of MLL1 or by pharmacological inhibition of the MLL1 methyltransferase complex. Our study reveals a novel chromatin mechanism underlying the progression of tumours with GOF p53, and suggests new possibilities for designing combinatorial chromatin-based therapies for treating individual cancers driven by prevalent GOF p53 mutations.

[1]  A. Inga,et al.  More targets, more pathways and more clues for mutant p53 , 2013, Oncogenesis.

[2]  I. Kubacka,et al.  Mutant p53 cooperates with ETS2 to promote etoposide resistance. , 2012, Genes & development.

[3]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[4]  Jianmin Wu,et al.  Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.

[5]  Thomas A Milne,et al.  Interaction of MLL amino terminal sequences with menin is required for transformation. , 2005, Cancer research.

[6]  Liu Liu,et al.  High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. , 2013, Journal of the American Chemical Society.

[7]  Lingyi Chen,et al.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells , 2009, Proceedings of the National Academy of Sciences.

[8]  Bing Li,et al.  The Role of Chromatin during Transcription , 2007, Cell.

[9]  Maksymilian Chruszcz,et al.  Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. , 2012, Blood.

[10]  V. Rotter,et al.  Pla2g16 phospholipase mediates gain-of-function activities of mutant p53 , 2014, Proceedings of the National Academy of Sciences.

[11]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[12]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[13]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[14]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[15]  Jolanta Grembecka,et al.  Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. , 2012, Nature chemical biology.

[16]  Washington Seattle.  An integrated encyclopedia of DNA elements in the human genome , 2016 .

[17]  Kajia Cao,et al.  Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape , 2013, Genes & development.

[18]  L. Ellisen,et al.  Molecular diagnostics , 2009, Nature Reviews Drug Discovery.

[19]  A. Shilatifard.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. , 2012, Annual review of biochemistry.

[20]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[21]  M. Scian,et al.  Modulation of Gene Expression by Tumor-Derived p53 Mutants , 2004, Cancer Research.

[22]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[23]  Timothy E. Reddy,et al.  Distinct properties of cell-type-specific and shared transcription factor binding sites. , 2013, Molecular cell.

[24]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[25]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[26]  P. Meltzer,et al.  A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis , 2014, Oncogene.

[27]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[28]  M. Lei,et al.  Menin as a hub controlling mixed lineage leukemia , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  A. Levine,et al.  Tumor-Associated Mutant p53 Drives the Warburg Effect , 2013, Nature Communications.

[30]  Tony Kouzarides,et al.  Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.

[31]  Wai Leong Tam,et al.  The epigenetics of epithelial-mesenchymal plasticity in cancer , 2013, Nature Medicine.

[32]  Zhaohui S. Qin,et al.  Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. , 2014, Molecular cell.

[33]  M. Lei,et al.  The same pocket in menin binds both MLL and JUND but has opposite effects on transcription , 2012, Nature.

[34]  A. Voss,et al.  Moz and retinoic acid coordinately regulate H3K9 acetylation, Hox gene expression, and segment identity. , 2009, Developmental cell.

[35]  G. Poda,et al.  Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5 , 2012, The Biochemical journal.

[36]  Madelaine Gogol,et al.  Global Analysis of H3K4 Methylation Defines MLL Family Member Targets and Points to a Role for MLL1-Mediated H3K4 Methylation in the Regulation of Transcriptional Initiation by RNA Polymerase II , 2009, Molecular and Cellular Biology.

[37]  Elizabeth C. Townsend,et al.  Analysis of the binding of mixed lineage leukemia 1 (MLL1) and histone 3 peptides to WD repeat domain 5 (WDR5) for the design of inhibitors of the MLL1-WDR5 interaction. , 2010, Journal of medicinal chemistry.

[38]  Toshiki Mori,et al.  ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. , 2002, Molecular cell.

[39]  G. Poda,et al.  Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia , 2015, Nature chemical biology.

[40]  Thomas A Milne,et al.  MLL targets SET domain methyltransferase activity to Hox gene promoters. , 2002, Molecular cell.

[41]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[42]  T. Silhavy,et al.  Genomic and Biochemical Insights into the Specificity of ETS Transcription Factors , 2017 .

[43]  Q. Zhu,et al.  Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to down-regulate transcriptional activity of p53. , 2001, Cancer research.

[44]  D. Proia,et al.  Improving survival by exploiting tumor dependence on stabilized mutant p53 for treatment , 2015, Nature.